Clinical Trials Logo

Clinical Trial Summary

The main purpose of the study is to see how safe the study drug AX-8 is and how well it is tolerated when administered at different dose levels in healthy participants.

The study will also investigate pharmacokinetics (PK), i.e how the study drug is taken up, metabolized (broken down) and eliminated.


Clinical Trial Description

The primary objective of the study is to investigate the safety and tolerability of ascending AX-8 oral doses, i.e. orally disintegrating tablets (ODTs), administrated twice for one day (Day 1) in healthy participants.

The secondary objectives are to investigate the pharmacokinetic (PK) profile and the subjective sensory attributes (e.g. basic tastes, palatability, cooling) of ascending AX-8 oral doses (ODTs), administered twice for one day in healthy participants.

The study consists of two parts.

Part 1

The first part of the study (Part 1) is an ascending dose, open-label, single center study in healthy participants. Part 1 will consist of a Screening Period (Days -28 to -1) to assess eligibility to participate in the study, 4 Treatment Periods (Day 1 to Day 2; one overnight stay for each treatment period) with a minimum washout period of 48 hours between doses (however a longer period will be required for dose escalation / safety review decisions, as required) and a Follow-Up Visit 7 to 14 days post last dose.

During each treatment period, participants will be admitted to the study center on the morning of Day 1 and discharged from the study center on the morning of Day 2 (i.e. after the pre-discharge procedures have been performed). Participants will attend a Follow-Up Visit (or Early Withdrawal Visit as applicable) to complete the study.

The end of the study will be the date of the last study visit for the last participant in the study (LPLV).

It is planned to include 10 eligible participants into Part 1 of the study to receive AX-8 ODTs administered orally which will be dissolved on the tongue (oromucosal route of administration). Participants will receive doses of AX-8 ODTs up to 80 mg/day, administered split over 2 dosing time points (i.e. 0 hour and + 8 hours), as follows:

- Treatment Period 1: 2 x 5 mg tablets, 10 mg total;

- Treatment Period 2: 2 x 10 mg tablets, 20 mg total;

- Treatment Period 3: 2 x 20 mg tablets, 40 mg total;

- Treatment Period 4: 2 x 40 mg tablets, 80 mg total.

Dosing in each sequential treatment period will be staggered; after the first 2 participants (i.e. sentinel group) are dosed there will be at least a 24-hour observation period from the morning dose (0 hour) before the remaining 8 participants are dosed. The remaining participants will be dosed if the sentinel group shows no clinically significant safety or tolerability concerns (including available safety electrocardiograms [ECGs], vital signs measurements, physical examinations and review of any adverse events [AEs]) at the discretion of the PI. Any clinically significant findings from the sentinel group in the opinion of the PI will be discussed with the Sponsor prior to dosing of the remaining 8 participants.

Dose escalation will be based on safety and tolerability data from each treatment period. In addition, available PK data from Treatment Period 1 (5 mg; twice daily) and Treatment Period 2 (10 mg; twice daily) will be used to support dose escalation decisions for Treatment Period 3 (20 mg; twice daily) and Treatment Period 4 (40 mg; twice daily).

Escalation to the next higher dose level (i.e. next sequential treatment period) will not take place until the site's PI and the Sponsor have determined that adequate safety and tolerability data from the previous treatment period has been demonstrated to permit proceeding to the next sequential treatment period (i.e. higher dose level). The minimum data package required for dose escalation decisions will include safety and tolerability data through Day 2 in a minimum of 6 participants (including available safety ECGs, vital signs measurements, physical examinations, clinical laboratory tests and review of any adverse events). Safety reports will be produced summarizing the safety data of the participants. The justification for selection of the dose will be prepared by the investigator for the proposed dose escalation and documented in the dose escalation meeting minutes.

Additional participants may be enrolled if it is deemed appropriate by the site's PI and the Sponsor to repeat a dose level or to study an intermediate dose level (lower than those planned). Repetition of a dose level will not be permitted for dose levels that met any of the stopping rules.

Part 2

The first part of the study (Part 1) has been completed, i.e. 10 participants were recruited and received AX-8 (10 mg to 80 mg/day) over 4 treatment periods (in a dose escalation regimen) and have attended their follow-up visits. The interim analysis of the study data from Part 1 has concluded that tablet dissolution time was too long, affecting systemic exposure to AX-8, probably due to the instructions for administration. Consequently, it was decided to re-evaluate the 5 mg and 40 mg AX-8 tablets with other administration instructions.

It is planned that 10 participants will be enrolled into Part 2 of the study to receive a total dose of 45 mg split into two doses on Day 1 (Dose 1 (5 mg): +0 h, Dose 2 (40 mg): + 8 h).

Part 2 will consist of a Screening Period (Days -28 to -1) to assess eligibility to participate in the study, 1 Treatment Period (Day 1 to Day 2; one overnight stay) and a Follow-Up Visit 7 to 14 days post last dose. There will be no dose escalation decisions nor dose staggering of participants as the doses to be administered in Part 2 are lower than the highest dose level administered in Part 1.

For Part 1 and Part 2; blood samples will be taken pre and post each dose to measure plasma concentrations of AX-8, despropyl AX-8 (metabolite C, MetC) and potentially other AX-8 metabolites and compounds. Subjective assessments to characterise the sensory attributes of the AX-8 ODTs (e.g. feeling factors and taste) will be performed pre and post each dose. Safety assessments will be performed throughout the study and will include monitoring adverse events (AEs), physical examinations, vital signs, 12-lead ECGs, and clinical laboratory tests.

The duration of the study will be approximately 65 days for subjects enrolled in Part 1 and approximately 44 days for subjects enrolled in Part 2; however, the actual duration will depend on the length of the screening period and the washout periods (as appropriate). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04107441
Study type Interventional
Source Axalbion SA
Contact
Status Completed
Phase Phase 1
Start date September 9, 2019
Completion date March 4, 2020

See also
  Status Clinical Trial Phase
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Recruiting NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1
Completed NCT04052711 - A Randomized, Controlled Study to Evaluate the Sensitizing Potential of FMX-101 in Healthy Volunteers Using a Repeat Insult Patch Test Design Phase 1
Terminated NCT00001844 - Study of New Magnetic Resonance Methods
Completed NCT04451811 - A PK Dose Proportionality Study of OPL-002 in Healthy Volunteers Phase 1
Completed NCT04319926 - Adhesion Performance Study of Lidocaine Topical System 1.8% Compared to Generic Lidocaine Patch 5% in Healthy, Adult, Human Subjects Phase 1
Completed NCT03160261 - Effect of Exenatide on Cortisol Secretion Phase 4
Completed NCT03662100 - A Study of Two Formulations of LY3074828 in Healthy Participants Phase 1
Recruiting NCT02875301 - Investigating Gains in Neurocognition in an Intervention Trial of Exercise Phase 3
Completed NCT01437592 - Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects Phase 1
Completed NCT03670082 - Study With Lu AF35700 in Healthy Men and Women in Fasting and Fed State Phase 1
Completed NCT03656952 - A Study to Evaluate the PF-06700841 Effect on QTc Interval in Healthy Volunteers Phase 1
Completed NCT03203824 - The Effects of Dark Chocolate (70% Cacao) on EEG Brain Waves in Vigorously Active Individuals N/A
Completed NCT03056846 - Probiotics on Stress-associated Gastrointestinal Function in University Students N/A